Aerie Pharmaceuticals (NSDQ:AERI) said today that it resubmit a New Drug Application for the company’s Rhopressa eye drops. The Irvine, Calif.-based company’s NDA was withdrawn in October last year, after a contract manufacturer was not prepared for its pre-approval inspection.
Aerie’s Rhopressa eye drops specifically target the eye’s trabecular network – the diseased tissue responsible for elevated intraocular pressure in patients with glaucoma.
Get the full story at our sister site, Drug Delivery Business News.
The post Aerie resubmits NDA for Rhopressa eye drops appeared first on MassDevice.